Jazz Pharmaceuticals (NASDAQ:JAZZ) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $337.00 price target on the specialty pharmaceutical company’s stock. The Goldman Sachs Group’s price target suggests a potential upside of 41.63% from the company’s previous close.

A number of other research firms have also recently commented on JAZZ. Barclays upped their target price on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Needham & Company LLC boosted their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Bank of America upped their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $289.37.

Jazz Pharmaceuticals Trading Up 0.7%

JAZZ stock traded up $1.67 during midday trading on Thursday, hitting $237.95. 1,129,591 shares of the company’s stock were exchanged, compared to its average volume of 945,530. Jazz Pharmaceuticals has a 1-year low of $125.79 and a 1-year high of $266.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $15.45 billion, a PE ratio of 16.41, a P/E/G ratio of 0.22 and a beta of 0.36. The business has a 50-day simple moving average of $248.98 and a two-hundred day simple moving average of $227.51.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same period last year, the company earned ($8.25) EPS. On average, sell-side analysts predict that Jazz Pharmaceuticals will post 21.5 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the sale, the director directly owned 351,875 shares of the company’s stock, valued at $88,014,493.75. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares in the company, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,121 shares of company stock valued at $24,443,842 over the last three months. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Sequoia Financial Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 9.4% in the second quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the specialty pharmaceutical company’s stock valued at $1,091,000 after acquiring an additional 389 shares in the last quarter. Tidal Investments LLC grew its stake in Jazz Pharmaceuticals by 8.3% during the 2nd quarter. Tidal Investments LLC now owns 21,028 shares of the specialty pharmaceutical company’s stock worth $5,067,000 after purchasing an additional 1,615 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $386,000. Integrated Wealth Concepts LLC increased its holdings in Jazz Pharmaceuticals by 27.2% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 1,762 shares of the specialty pharmaceutical company’s stock worth $425,000 after purchasing an additional 377 shares during the period. Finally, NewEdge Advisors LLC raised its position in Jazz Pharmaceuticals by 15.7% in the 2nd quarter. NewEdge Advisors LLC now owns 2,285 shares of the specialty pharmaceutical company’s stock valued at $551,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.